Technical analysis of Protalix BioTherapeutics, Inc. (PLX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Price Performance
| 1 month | +14.53% |
| 3 months | +20.72% |
| Year-to-date | +48.89% |
| 1 year | +43.32% |
| 3 years | +54.91% |
| 5 years | +91.43% |
52-Week Range
| 52-week High | $3.19 |
| 52-week Low | $1.60 |
| Avg Volume (90d) | 725K |
Technical Indicators
| SMA 50 | $2.45 |
| SMA 200 | $2.28 |
| Beta | -0.09 |
| 30-day Volatility (annualised) | 53.3% |
| Price vs SMA 50 | +9.3% |
| Price vs SMA 200 | +17.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.37 | |
| 2025-11 | $1.78 | -24.9% |
| 2025-12 | $1.80 | +1.1% |
| 2026-01 | $2.34 | +30.0% |
| 2026-02 | $2.88 | +23.1% |
| 2026-03 | $2.17 | -24.7% |
| 2026-04 | $2.15 | -0.9% |
| 2026-05 | $2.11 | -1.9% |
| 2026-06 | $2.33 | +10.4% |
| 2026-07 | $2.37 | +1.7% |
| 2026-08 | $2.57 | +8.4% |
| 2026-09 | $2.68 | +4.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.68 |
| Market Cap | $216M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| P/E Ratio | 11.12 |
| Price / Book | 3.00 |
| EV / EBITDA | 7.49 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 2.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.05 |